LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $1.97M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +136.0% a year.
Context
- Other current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.91M USD
- Year-over-year change
- +29.6%
- 3-year CAGR
- +136.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.91M | +29.6% |
| FY2024 | 2024-12-31 | 2.24M | +180.8% |
| FY2023 | 2023-12-31 | 798K | +261.1% |
| FY2022 | 2022-12-31 | 221K | — |
Other Current Liabilities vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 other current liabilities of $1.97M is the 9th highest of the 10 companies compared; the peer median is $11.15M.
- Other current liabilities amounts to 0.5% of total assets for LBRX, versus a peer median of 2.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +450133.7% | — | 4.2% | |
| Sep 2026 | $332.22M | +16.5% | +11.1% | 18.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $24.77M | +294.3% | +42.0% | 16.1% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $21.33M | -53.2% | +67.6% | 2.0% |
| Mar 2026 | $11.15M | +65.0% | +89.8% | 2.7% | |
| Mar 2026 | $7.61M | — | +35.8% | 2.8% | |
| Mar 2026 | $6.25M | +29.9% | +9.3% | 2.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $3.08M | +46.6% | — | 0.6% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.97M | — | +136.0% | 0.5% |
| Jun 2026 | $0 | -100.0% | +46.1% | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $11.15M | +38.2% | +42.0% | 2.7% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.